Use of Venetoclax Combination Regimens in Chronic Lymphocytic Leukemia

H&O Is single-agent venetoclax a common treatment for chronic lymphocytic leukemia (CLL)? CT In CLL, venetoclax (Venclexta, AbbVie/Genentech) is typically not used as a single agent; […]

How I Manage Chronic Lymphocytic Leukemia

Introduction The therapeutic landscape for chronic lymphocytic leukemia (CLL) has changed dramatically in the last several years.1 The role of chemoimmunotherapy has declined, and we are […]

Choosing Between Novel Agents and Chemoimmunotherapy in CLL

H&O Which novel agents are available for physicians treating patients with chronic lymphocytic leukemia? JW Right now, we have Bruton tyrosine kinase (BTK) inhibitors, phosphoinositide-3 […]

CLL In Focus

CLL Linked to Elevated Risk for Second Cancers Even With BTK Inhibition Patients with chronic lymphocytic leukemia (CLL) are at increased risk for second cancers even […]

The Evolving Use of Minimal Residual Disease (MRD) Assessment in Chronic Lymphocytic Leukemia

Abstract: The treatment of chronic lymphocytic leukemia (CLL) has changed remarkably throughout the past decade, with patients achieving deeper and more durable responses. Importantly, this clinical activity […]

Richter Transformation of Chronic Lymphocytic Leukemia in the Era of Novel Agents

Abstract: The increased use of several effective novel targeted therapy agents has revolutionized therapy for patients with chronic lymphocytic leukemia (CLL). Disease progression in patients […]

Highlights in Chronic Lymphocytic Leukemia From the 61st American Society of Hematology Annual Meeting and Exposition

A Review of Selected Presentations From the 61st ASH Meeting • December 7-10, 2019 • Orlando, Florida ELEVATE TN: Phase 3 Study of Acalabrutinib Combined […]

Venetoclax, the First BCL-2 Inhibitor for Use in Patients With Chronic Lymphocytic Leukemia

H&O What is the mechanism of action for venetoclax, and why is it suited for chronic lymphocytic leukemia (CLL)? JS Venetoclax (Venclexta, AbbVie/Genentech) has a […]

Highlights in Chronic Lymphocytic Leukemia From the 2019 American Society of Clinical Oncology Annual Meeting

A Review of Selected Presentations From the 2019 ASCO Annual Meeting • May 31-June 4, 2019 • Chicago, Illinois Final Analysis From RESONATE: Six-Year Follow-Up in […]

Optimizing Drug Dosing for the Treatment of Chronic Lymphocytic Leukemia

H&O What drugs are available to treat chronic lymphocytic leukemia? NJ The treatment paradigm for chronic lymphocytic leukemia (CLL) has changed substantially in the past […]

Does FCR Have the Potential to Cure a Subgroup of Patients With Chronic Lymphocytic Leukemia?

H&O When is first-line treatment initiated in patients with CLL? WW In chronic lymphocytic leukemia (CLL), patients should meet a standard criteria to initiate treatment. […]

Zanubrutinib: A Novel BTK Inhibitor in Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma

H&O What type of drug is zanubrutinib? CT Zanubrutinib, also known as BGB-3111, is a next-generation Bruton’s tyrosine kinase (BTK) inhibitor. It inhibits BTK irreversibly […]

Hem/Onc News

Duvelisib Approved in Relapsed/Refractory CLL, SLL, and FL The US Food and Drug Administration (FDA) approved duvelisib (Copiktra, Verastem) on September 24 for adults with relapsed […]

Immune-Mediated Hemolytic Anemia and Thrombocytopenia in Clonal B-Cell Disorders: A Review

Abstract: Autoimmune hemolytic anemia (AIHA) and immune thrombocytopenia purpura (ITP) have been associated with B-cell lymphoproliferative disorders. Here, we review the epidemiology, pathogenesis, diagnosis, and […]

Hem/Onc News

First Biosimilar to Pegfilgrastim Approved to Decrease Risk for Infection During Cancer Treatment On June 4, the US Food and Drug Administration (FDA) approved pegfilgrastim-jmdb (Fulphila, […]

Update on Signal Inhibitors in Chronic Lymphocytic Leukemia

Abstract: The last decade has seen major progress in our understanding of the pathobiology of chronic lymphocytic leukemia (CLL) and the identification of potential new […]

Advances in CAR T-Cell Therapy for Chronic Lymphocytic Leukemia

H&O How does CAR T-cell therapy work? DP A patient’s T cells are removed through leukapheresis and then genetically modified in the laboratory so that […]

BCL-2 As a Therapeutic Target in Chronic Lymphocytic Leukemia

Abstract: Venetoclax (formerly ABT-199) was recently approved in the United States for the treatment of patients who have relapsed or refractory chronic lymphocytic leukemia (CLL) […]

Considerations in the Frontline Treatment of Chronic Lymphocytic Leukemia

H&O When is frontline therapy initiated in chronic lymphocytic leukemia (CLL)? SO The standard approach to CLL is still watch-and-wait. If patients are asymptomatic and […]